Taking this into account, Robert W. Baird downgraded its Carisma Therapeutics Inc [CARM] rating to a Neutral from a an Outperform in a research note published on December 12, 2024; the price target was decreased to $1 from $10. A number of analysts have revised their coverage, including BTIG Research’s analysts, who decreased its forecast for the stock in early December from “a Buy” to “a Neutral”. BTIG Research began covering CARM with “Buy” recommendation on April 11, 2024. CapitalOne started covering the stock on October 03, 2023. It rated CARM as “an Overweight”.
Price Performance Review of CARM
On Tuesday, Carisma Therapeutics Inc [NASDAQ:CARM] saw its stock fall -3.73% to $0.19. Over the last five days, the stock has lost -16.46%. Carisma Therapeutics Inc shares have fallen nearly -55.64% since the year began. Nevertheless, the stocks have fallen -87.70% over the past one year. While a 52-week high of $1.90 was reached on 01/07/25, a 52-week low of $0.16 was recorded on 04/07/25. SMA at 50 days reached $0.2831, while 200 days put it at $0.6643.
Levels Of Support And Resistance For CARM Stock
The 24-hour chart illustrates a support level at 0.1688, which if violated will result in even more drops to 0.1518. On the upside, there is a resistance level at 0.1989. A further resistance level may holdings at 0.2120. The Relative Strength Index (RSI) on the 14-day chart is 37.11, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.0206, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 78.85%. Stochastics %K at 20.66% indicates the stock is a holding.
The most recent change occurred on July 06, 2023 when Evercore ISI began covering the stock and recommended ‘”an Outperform”‘ rating along with a $12 price target.
